Pre-Open Stock Movers 12/01: (VBIV) (AMBA) (BOX) Higher; (BTAI) (CTIC) (CRM) Lower (more...)

December 1, 2021 9:19 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Pre-Open Stock Movers:

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) 17.4% LOWER; announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.

VBI Vaccines Inc. (Nasdaq: VBIV) 16.1% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved PreHevbrio [Hepatitis B Vaccine (Recombinant)] for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older. PreHevbrio contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the U.S.

Ambarella (NASDAQ: AMBA) 16% HIGHER; reported Q3 EPS of $0.57, $0.08 better than the analyst estimate of $0.49. Revenue for the quarter came in at $92.2 million versus the consensus estimate of $90.35 million. Ambarella sees Q4 2022 revenue of $88.5-91.5 million, versus the consensus of $88.22 million.

CTI BioPharma Corp. (Nasdaq: CTIC) 12.4% LOWER; announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109/L. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.

Box (NYSE: BOX) 12% HIGHER; reported Q3 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $224 million versus the consensus estimate of $218.49 million. Box sees Q4 2022 EPS of $0.22-$0.23, versus the consensus of $0.22. Box sees Q4 2022 revenue of $227-229 million, versus the consensus of $222.93 million. Box sees FY2022 EPS of $0.83-$0.84, versus the consensus of $0.81. Box sees FY2022 revenue of $868-870 million, versus the consensus of $858.51 million.

Salesforce (NYSE: CRM) 6% LOWER; reported Q3 EPS of $1.27, $0.35 better than the analyst estimate of $0.92. Revenue for the quarter came in at $6.86 billion versus the consensus estimate of $6.79 billion. Salesforce sees Q4 2022 EPS of $0.72-$0.73, versus the consensus of $0.81. Salesforce sees Q4 2022 revenue of $7.224-7.234 billion, versus the consensus of $7.22 billion.

ImmunoGen Inc. (Nasdaq: IMGN) 5.5% LOWER; intends to offer and sell, subject to market and other conditions, $175 million of shares of its common stock in an underwritten public offering.

Zscaler (NASDAQ: ZS) 4.6% HIGHER; reported Q1 EPS of $0.14, $0.02 better than the analyst estimate of $0.12. Revenue for the quarter came in at $230.5 million versus the consensus estimate of $208.43 million. Zscaler sees Q2 2022 EPS of $0.11, versus the consensus of $0.12. Zscaler sees Q2 2022 revenue of $240-242 million, versus the consensus of $221.15 million. Zscaler sees FY2022 EPS of $0.50-$0.52, versus the consensus of $0.56. Zscaler sees FY2022 revenue of $1-1.01 billion, versus the consensus of $0.94156 billion.

Hewlett Packard Enterprise (NYSE: HPE) 2.4% LOWER; reported Q4 EPS of $0.52, $0.03 better than the analyst estimate of $0.49. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $7.39 billion. Hewlett Packard Enterprise sees Q1 2022 EPS of $0.42-$0.50, versus the consensus of $0.49. Hewlett Packard Enterprise sees FY2022 EPS of $1.96-$2.10, versus the consensus of $2.03.

NetApp (NASDAQ: NTAP) 1.2% HIGHER; reported Q2 EPS of $1.28, $0.07 better than the analyst estimate of $1.21. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.55 billion. NetApp sees Q3 2022 EPS of $1.21-$1.31, versus the consensus of $1.28. NetApp sees Q3 2022 revenue of $1.53-1.68 billion, versus the consensus of $1.59 billion. NetApp sees FY2022 EPS of $4.90-$5.10, versus the consensus of $5.01.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

S1, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, PDUFA, FDA